Merus NV
NASDAQ:MRUS

Watchlist Manager
Merus NV Logo
Merus NV
NASDAQ:MRUS
Watchlist
Price: 39.45 USD -0.5% Market Closed
Market Cap: 2.7B USD

Merus NV
Investor Relations

Merus NV, a Dutch biotechnology company, stands at the forefront of innovative cancer therapies, channeling its efforts into research and development of multispecific antibodies. Its proprietary technology platform, Biclonics®, ingeniously harnesses the power of full-length human antibodies to target multiple pathways in the treatment of cancer. Each Biclonics® candidate is designed to bind simultaneously to more than one target, acting like a precision-guided missile that seeks out cancer cells and disrupts the signaling processes that allow tumors to grow and spread. This cutting-edge approach aims to overcome the limitations of traditional monoclonal antibodies and offers promising new avenues for tackling cancer’s incessant complexity.

The company's business model is built upon a robust pipeline strategy, where promising drug candidates are both developed in-house and guided through strategic collaborations with larger pharmaceutical entities. These collaborations often involve licensing agreements that provide Merus NV with milestone payments and royalties, creating a significant revenue stream. As these partnerships amplify its reach and bolster its financial health, Merus maintains a primary focus on advancing its leading drug candidates through clinical trials. By aligning groundbreaking science with strategic collaborations, Merus NV works to convert its innovations into viable products that can potentially transform the landscape of cancer treatment, striving to turn scientific potential into practical solutions and profitable outcomes.

Show more
Loading

Earnings Calls

No Earnings Calls Available

Management

Dr. Sven Ante Lundberg M.D.
CEO, President & Executive Director
No Bio Available
Mr. Gregory D. Perry
Chief Financial Officer
No Bio Available
Mr. Peter B. Silverman J.D.
EVP, Company Secretary, COO, General Counsel, Chief Intellectual Property Officer & Head of US Legal
No Bio Available
Dr. Hennie Hoogenboom
Co-Founder and Scientific Advisor
No Bio Available
Harry Shuman
Chief Accounting Officer
No Bio Available
Mr. Cornelis Adriaan de Kruif Ph.D.
CTO & Executive VP
No Bio Available
Dr. Cecilia Anna Wilhelmina Geuijen Ph.D.
Chief Scientific Officer & Senior VP
No Bio Available
Ms. Kathleen Farren
IR & Corporate Communications Officer
No Bio Available
Ms. Audrey Bergan
Chief People Officer
No Bio Available
Ms. Shannon Campbell
Executive VP & Chief Commercial Officer
No Bio Available

Contacts

Address
UTRECHT
Utrecht
Yalelaan 62
Contacts
+31850162500.0
www.merus.nl